Contact
searchSearch
HMP Global
Login

Prostate Cancer

Prostate Cancer
Specialty Channel
Kim Chi, MD
Videos
PR21 PLUTO Supports Flexible Sequencing of Docetaxel and Lutetium-177 PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
06/19/2026
Kim Chi, MD
Kim Chi, MD, discusses crossover analysis results from the PR21 PLUTO trial showing that patients with PSMA-positive metastatic castration-resistant prostate cancer experienced similar progression-free and overall survival outcomes regardless...
Kim Chi, MD, discusses crossover analysis results from the PR21 PLUTO trial showing that patients with PSMA-positive metastatic castration-resistant prostate cancer experienced similar progression-free and overall survival outcomes regardless...
Kim Chi, MD, discusses crossover...
06/19/2026
Radiopharmaceutical Education Institute
From Radiopharmaceutical Education Institute
David Cade, MD
Videos
TLX591 Shows Prolonged Tumor Retention With Limited Off-Target Radiation Exposure in Metastatic Castration-Resistant Prostate Cancer
06/19/2026
David Cade, MD
David Cade, MD, discusses the phase 3 PROSTACT Global trial evaluating TLX591, a PSMA-targeted radio-antibody drug conjugate that demonstrated favorable safety, dosimetry, and tumor-retention characteristics and is being developed for...
David Cade, MD, discusses the phase 3 PROSTACT Global trial evaluating TLX591, a PSMA-targeted radio-antibody drug conjugate that demonstrated favorable safety, dosimetry, and tumor-retention characteristics and is being developed for...
David Cade, MD, discusses the...
06/19/2026
Radiopharmaceutical Education Institute
From Radiopharmaceutical Education Institute
Neeraj Agarwal, MD
Videos
TALAPRO-3 Establishes Talazoparib Plus Enzalutamide as a New Standard for HRR-Altered Metastatic Hormone-Sensitive Prostate Cancer
06/18/2026
Neeraj Agarwal, MD
Neeraj Agarwal, MD, discusses results from the phase 3 TALAPRO-3 trial showing that talazoparib plus enzalutamide reduced the risk of radiographic progression or death by 52% and significantly delayed disease progression across BRCA and...
Neeraj Agarwal, MD, discusses results from the phase 3 TALAPRO-3 trial showing that talazoparib plus enzalutamide reduced the risk of radiographic progression or death by 52% and significantly delayed disease progression across BRCA and...
Neeraj Agarwal, MD, discusses...
06/18/2026
Oncology
Michael Morris, MD
Videos
Convo-1α Produces Durable Responses in Patients Previously Treated With PSMA Radioligand Therapy
06/18/2026
Michael Morris, MD
Michael Morris, MD, discusses results from a phase 2 study showing that the actinium-225 PSMA-targeted radio-antibody conjugate Convo-1α achieved durable responses lasting up to 12 months with limited xerostomia and no nephrotoxicity in...
Michael Morris, MD, discusses results from a phase 2 study showing that the actinium-225 PSMA-targeted radio-antibody conjugate Convo-1α achieved durable responses lasting up to 12 months with limited xerostomia and no nephrotoxicity in...
Michael Morris, MD, discusses...
06/18/2026
Radiopharmaceutical Education Institute
From Radiopharmaceutical Education Institute
FDA Approval
FDA Approves Capivasertib Plus Abiraterone for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer
06/12/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA has approved capivasertib plus abiraterone and prednisone for adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is...
Based on results from the phase 3 CAPItello-281 trial, the FDA has approved capivasertib plus abiraterone and prednisone for adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is...
Based on results from the phase...
06/12/2026
Oncology
Alicia Morgans, MD
Videos
Enzalutamide Associated with Increased Cognitive Decline in in Advanced Prostate Cancer
06/12/2026
Alicia Morgans, MD
Alicia Morgans, MD, discusses results from the ARACOG trial which demonstrated that greater enzalutamide was associated with greater cognitive decline compared with darolutamide in patients with advanced prostate cancer.
Alicia Morgans, MD, discusses results from the ARACOG trial which demonstrated that greater enzalutamide was associated with greater cognitive decline compared with darolutamide in patients with advanced prostate cancer.
Alicia Morgans, MD, discusses...
06/12/2026
Oncology
News
Talazoparib Plus Enzalutamide Reduces Risk of Radiographic Progression in HRR-Deficient Metastatic Castration-Sensitive Prostate Cancer
05/30/2026
Stephanie Holland
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3...
05/30/2026
Oncology
Mark Garzotto, MD
Videos
Intratumoral Adenoviral Therapy Combined With Radiation in Prostate Cancer
05/27/2026
Mark Garzotto, MD
Mark Garzotto, MD, discusses a novel intratumoral adenoviral therapy combined with radiotherapy for patients with intermediate- and high-risk prostate cancer.
Mark Garzotto, MD, discusses a novel intratumoral adenoviral therapy combined with radiotherapy for patients with intermediate- and high-risk prostate cancer.
Mark Garzotto, MD, discusses a...
05/27/2026
Oncology
News
Extended Pelvic Lymph Node Dissection Shows Selective Benefit in Patients With Prostate Cancer
05/22/2026
Emily Estrada
Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...
Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...
Long-term results from a phase 3...
05/22/2026
Oncology
News
Aglatimagene Improves Disease-Free Survival in Patients With Localized Prostate Cancer
05/20/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that aglatimagene improved prostate cancer-specific survival when added to standard external beam radiotherapy with or without androgen deprivation therapy in localized prostate cancer.
Results from a phase 3 trial demonstrated that aglatimagene improved prostate cancer-specific survival when added to standard external beam radiotherapy with or without androgen deprivation therapy in localized prostate cancer.
Results from a phase 3 trial...
05/20/2026
Oncology
Rana McKay, MD
Videos
Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer
05/19/2026
Rana McKay, MD
Rana McKay, MD, discusses results from the ARASEC trial evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.
Rana McKay, MD, discusses results from the ARASEC trial evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.
Rana McKay, MD, discusses...
05/19/2026
Oncology

News

FDA Approval
FDA Approves Capivasertib Plus Abiraterone for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer
06/12/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA has approved capivasertib plus abiraterone and prednisone for adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is...
Based on results from the phase 3 CAPItello-281 trial, the FDA has approved capivasertib plus abiraterone and prednisone for adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is...
Based on results from the phase...
06/12/2026
Oncology
News
Talazoparib Plus Enzalutamide Reduces Risk of Radiographic Progression in HRR-Deficient Metastatic Castration-Sensitive Prostate Cancer
05/30/2026
Stephanie Holland
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3...
05/30/2026
Oncology
News
Extended Pelvic Lymph Node Dissection Shows Selective Benefit in Patients With Prostate Cancer
05/22/2026
Emily Estrada
Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...
Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...
Long-term results from a phase 3...
05/22/2026
Oncology
News
Aglatimagene Improves Disease-Free Survival in Patients With Localized Prostate Cancer
05/20/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that aglatimagene improved prostate cancer-specific survival when added to standard external beam radiotherapy with or without androgen deprivation therapy in localized prostate cancer.
Results from a phase 3 trial demonstrated that aglatimagene improved prostate cancer-specific survival when added to standard external beam radiotherapy with or without androgen deprivation therapy in localized prostate cancer.
Results from a phase 3 trial...
05/20/2026
Oncology
FDA Alerts
Capivasertib Gains Support from the FDA’s Advisory Committee in Metastatic Hormone-Sensitive Prostate Cancer
05/04/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase...
05/04/2026
Oncology
News
G-CSF Supports Effective Docetaxel Delivery in Metastatic Hormone-Sensitive Prostate Cancer
04/29/2026
Emily Estrada
Post hoc analysis results from the phase 3 ARASENS trial demonstrate that early G-CSF use and appropriate dose modifications allow most patients with metastatic hormone-sensitive prostate cancer to maintain effective docetaxel dosing with...
Post hoc analysis results from the phase 3 ARASENS trial demonstrate that early G-CSF use and appropriate dose modifications allow most patients with metastatic hormone-sensitive prostate cancer to maintain effective docetaxel dosing with...
Post hoc analysis results from...
04/29/2026
Oncology
News
131I-LNTH-1095 Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
04/10/2026
Stephanie Holland
Results from the phase 2 ARROW study demonstrated that enzalutamide plus radioligand therapy with 131I-LNTH-1095 significantly improved PSA50 in previously treated patients with metastatic castration-resistant prostate cancer.
Results from the phase 2 ARROW study demonstrated that enzalutamide plus radioligand therapy with 131I-LNTH-1095 significantly improved PSA50 in previously treated patients with metastatic castration-resistant prostate cancer.
Results from the phase 2 ARROW...
04/10/2026
Radiopharmaceutical Education Institute
News
Transdermal Estradiol Noninferior to LHRH Agonists in Locally Advanced Prostate Cancer
04/01/2026
Stephanie Holland
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study...
04/01/2026
Oncology
FDA Approval
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
News
Cabazitaxel Added to ADT and Radiotherapy Fails to Improve PFS in Localized Prostate Cancer
02/26/2026
Stephanie Holland
Results from the phase 3 PEACE-2 trial demonstrated that adding cabazitaxel to long-term androgen deprivation therapy (ADT) and radiotherapy does not improve progression-free survival in very high-risk localized prostate cancer.
Results from the phase 3 PEACE-2 trial demonstrated that adding cabazitaxel to long-term androgen deprivation therapy (ADT) and radiotherapy does not improve progression-free survival in very high-risk localized prostate cancer.
Results from the phase 3 PEACE-2...
02/26/2026
Oncology

Interactive Features

FDA Alerts
Capivasertib Gains Support from the FDA’s Advisory Committee in Metastatic Hormone-Sensitive Prostate Cancer
05/04/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase...
05/04/2026
Oncology
Quiz
Improving Detection of Clinically Significant Prostate Cancer
01/15/2024
True or False: Adding the PRIMARY score for patients with Prostate Imaging Reporting and Data System (PI-RADS) 4/5 showed a net benefit in detecting clinically significant prostate cancer.
True or False: Adding the PRIMARY score for patients with Prostate Imaging Reporting and Data System (PI-RADS) 4/5 showed a net benefit in detecting clinically significant prostate cancer.
True or False: Adding the...
01/15/2024
Oncology
Quiz
Adjuvant Radiotherapy Following Radical Prostatectomy
11/13/2023
Allison Casey
Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.
Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.
Test your knowledge on the...
11/13/2023
Oncology
Quiz
Biweekly vs Triweekly Cabazitaxel for Patients With Metastatic Castration-Resistant Prostate Cancer
11/10/2023
Test your knowledge with this quiz on the biweekly cabazitaxel regimen used in the phase 3 CASBASTY trial, for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this quiz on the biweekly cabazitaxel regimen used in the phase 3 CASBASTY trial, for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this...
11/10/2023
Oncology
Quiz
Adaptive 177Lu-PSMA-617 Dosing in the ENZA-p Trial
11/10/2023
Test your knowledge with this quiz on the adaptive dosing utilized in the ENZA-p trial, evaluating the addition of 177Lu-PSMA-617 to enzalutamide for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this quiz on the adaptive dosing utilized in the ENZA-p trial, evaluating the addition of 177Lu-PSMA-617 to enzalutamide for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this...
11/10/2023
Oncology
Quiz
True or False: A study found that the risk of prostate cancer following a transurethral resection of the prostate with a benign histology was higher than the risk for patients with a negative prostate biopsy.
11/02/2022
True or False: A study found that the risk of prostate cancer following a transurethral resection of the prostate with a benign histology was higher than the risk for patients with a negative prostate biopsy.
True or False: A study found that the risk of prostate cancer following a transurethral resection of the prostate with a benign histology was higher than the risk for patients with a negative prostate biopsy.
True or False: A study found...
11/02/2022
Oncology
Quiz
Quiz: Enzalutamide Plus Testosterone Suppression for Metastatic Hormone-Sensitive Prostate Cancer
09/02/2022
In the ENZAMET trial evaluating the addition of enzalutamide to testosterone suppression for patients with metastatic hormone-sensitive prostate cancer, did the extended follow-up find that the benefit from enzalutamide was sustained at the...
In the ENZAMET trial evaluating the addition of enzalutamide to testosterone suppression for patients with metastatic hormone-sensitive prostate cancer, did the extended follow-up find that the benefit from enzalutamide was sustained at the...
In the ENZAMET trial evaluating...
09/02/2022
Oncology
Quiz
Quiz: Does the Polaris Test Prognosticate Risk of Metastasis in Prostate Cancer?
07/21/2022
Quiz: The commercially-available Polaris test was able to prognosticate the risk of metastasis in which patients with prostate cancer?
Quiz: The commercially-available Polaris test was able to prognosticate the risk of metastasis in which patients with prostate cancer?
Quiz: The commercially-available...
07/21/2022
Oncology
Test Your Knowledge
Quiz: Can the Prolaris Test Estimate Metastasis in Prostate Cancer?
09/02/2021
True or false: For patients with intermediate or high-risk prostate cancer, the Prolaris test can provide an extremely precise and accurate risk estimate of metastasis after radiation therapy.
True or false: For patients with intermediate or high-risk prostate cancer, the Prolaris test can provide an extremely precise and accurate risk estimate of metastasis after radiation therapy.
True or false: For patients with...
09/02/2021
Oncology
Test Your Knowledge
Quiz: Can Large Antibodies Target PSMA Expression During mCRPC Treatment?
07/29/2021
True or False: Since small molecule ligands can target PSMA expression, this indicates that large antibodies cannot during mCRPC treatment.
True or False: Since small molecule ligands can target PSMA expression, this indicates that large antibodies cannot during mCRPC treatment.
True or False: Since small...
07/29/2021
Oncology

Recent News

FDA Approval
FDA Approves Capivasertib Plus Abiraterone for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer
06/12/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA has approved capivasertib plus abiraterone and prednisone for adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is...
Based on results from the phase 3 CAPItello-281 trial, the FDA has approved capivasertib plus abiraterone and prednisone for adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is...
Based on results from the phase...
06/12/2026
Oncology
News
Talazoparib Plus Enzalutamide Reduces Risk of Radiographic Progression in HRR-Deficient Metastatic Castration-Sensitive Prostate Cancer
05/30/2026
Stephanie Holland
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3 TALAPRO-3 trial demonstrated that talazoparib plus enzalutamide significantly improved radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
Results from the phase 3...
05/30/2026
Oncology
News
Extended Pelvic Lymph Node Dissection Shows Selective Benefit in Patients With Prostate Cancer
05/22/2026
Emily Estrada
Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...
Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...
Long-term results from a phase 3...
05/22/2026
Oncology
News
Aglatimagene Improves Disease-Free Survival in Patients With Localized Prostate Cancer
05/20/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that aglatimagene improved prostate cancer-specific survival when added to standard external beam radiotherapy with or without androgen deprivation therapy in localized prostate cancer.
Results from a phase 3 trial demonstrated that aglatimagene improved prostate cancer-specific survival when added to standard external beam radiotherapy with or without androgen deprivation therapy in localized prostate cancer.
Results from a phase 3 trial...
05/20/2026
Oncology
FDA Alerts
Capivasertib Gains Support from the FDA’s Advisory Committee in Metastatic Hormone-Sensitive Prostate Cancer
05/04/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase...
05/04/2026
Oncology
News
G-CSF Supports Effective Docetaxel Delivery in Metastatic Hormone-Sensitive Prostate Cancer
04/29/2026
Emily Estrada
Post hoc analysis results from the phase 3 ARASENS trial demonstrate that early G-CSF use and appropriate dose modifications allow most patients with metastatic hormone-sensitive prostate cancer to maintain effective docetaxel dosing with...
Post hoc analysis results from the phase 3 ARASENS trial demonstrate that early G-CSF use and appropriate dose modifications allow most patients with metastatic hormone-sensitive prostate cancer to maintain effective docetaxel dosing with...
Post hoc analysis results from...
04/29/2026
Oncology
News
131I-LNTH-1095 Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
04/10/2026
Stephanie Holland
Results from the phase 2 ARROW study demonstrated that enzalutamide plus radioligand therapy with 131I-LNTH-1095 significantly improved PSA50 in previously treated patients with metastatic castration-resistant prostate cancer.
Results from the phase 2 ARROW study demonstrated that enzalutamide plus radioligand therapy with 131I-LNTH-1095 significantly improved PSA50 in previously treated patients with metastatic castration-resistant prostate cancer.
Results from the phase 2 ARROW...
04/10/2026
Radiopharmaceutical Education Institute
News
Transdermal Estradiol Noninferior to LHRH Agonists in Locally Advanced Prostate Cancer
04/01/2026
Stephanie Holland
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study...
04/01/2026
Oncology
FDA Approval
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
News
Cabazitaxel Added to ADT and Radiotherapy Fails to Improve PFS in Localized Prostate Cancer
02/26/2026
Stephanie Holland
Results from the phase 3 PEACE-2 trial demonstrated that adding cabazitaxel to long-term androgen deprivation therapy (ADT) and radiotherapy does not improve progression-free survival in very high-risk localized prostate cancer.
Results from the phase 3 PEACE-2 trial demonstrated that adding cabazitaxel to long-term androgen deprivation therapy (ADT) and radiotherapy does not improve progression-free survival in very high-risk localized prostate cancer.
Results from the phase 3 PEACE-2...
02/26/2026
Oncology
News
Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma
06/26/2026
Emily Estrada
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an...
06/26/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients...
06/25/2026
Oncology
News
Pirtobrutinib Demonstrates Durable Clinical Activity in Relapsed or Refractory Waldenström Macroglobulinemia
06/25/2026
Stephanie Holland
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN...
06/25/2026
Oncology
News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Bulumtatug Fuvedotin Demonstrates Durable Activity in Previously Treated Cervical Cancer
06/23/2026
Emily Estrada
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2...
06/23/2026
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Patients With Unresectable or Metastatic Synovial Sarcoma
06/23/2026
Stephanie Holland
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the...
06/23/2026
Oncology
News
Signatera-Based ctDNA Testing Incorporated Into NCCN Bladder Cancer Guidelines
06/23/2026
Stephanie Holland
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use